122 related articles for article (PubMed ID: 15572728)
21. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling.
Kojima T; Shimazui T; Hinotsu S; Joraku A; Oikawa T; Kawai K; Horie R; Suzuki H; Nagashima R; Yoshikawa K; Michiue T; Asashima M; Akaza H; Uchida K
Oncogene; 2009 Jan; 28(2):297-305. PubMed ID: 18931698
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic indication of interferons for renal cell carcinoma].
Harano M; Naito S
Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
[No Abstract] [Full Text] [Related]
24. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
Shaheen PE; Bukowski RM
Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of an imidazoquinoline in renal cell carcinoma.
Schwartz MJ; Liu H; Hwang DH; Kawamoto H; Scherr DS
Urology; 2009 May; 73(5):1156-62. PubMed ID: 19118885
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson TE
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
[TBL] [Abstract][Full Text] [Related]
28. [Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].
Junker K; Sanjmyatav J; Heinze C; Walter M; Heinzelmann J; Wunderlich H; Schubert J; Steiner T
Urologe A; 2008 Sep; 47(9):1187-9. PubMed ID: 18688592
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy of renal cell cancer.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
[TBL] [Abstract][Full Text] [Related]
30. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.
Newton HB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):355-78. PubMed ID: 15877531
[TBL] [Abstract][Full Text] [Related]
31. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
32. New drug therapies for advanced renal cell carcinoma.
Gore ME; Harrison ML; Montes A
Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
[TBL] [Abstract][Full Text] [Related]
33. Microarray analysis of microRNA expression in renal clear cell carcinoma.
Huang Y; Dai Y; Yang J; Chen T; Yin Y; Tang M; Hu C; Zhang L
Eur J Surg Oncol; 2009 Oct; 35(10):1119-23. PubMed ID: 19443172
[TBL] [Abstract][Full Text] [Related]
34. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
Vassilakos A; Lee Y; Viau S; Feng N; Jin H; Chai V; Wang M; Avolio T; Wright J; Young A
Int J Oncol; 2009 Jan; 34(1):33-42. PubMed ID: 19082475
[TBL] [Abstract][Full Text] [Related]
35. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
36. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
38. The end of chemotherapy in renal cell carcinoma: for much but not for all.
Iacovelli R; Raimondi C; Palazzo A
Am J Clin Oncol; 2010 Oct; 33(5):522-3. PubMed ID: 20924226
[No Abstract] [Full Text] [Related]
39. Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment.
Khasawneh MK; Bukowski RM
Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S7-S18. PubMed ID: 17239285
[TBL] [Abstract][Full Text] [Related]
40. Emerging drugs for renal cell carcinoma.
Shaheen PE; Bukowski RM
Expert Opin Emerg Drugs; 2005 Nov; 10(4):773-95. PubMed ID: 16262562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
